الصفحة الرئيسية>>Signaling Pathways>> Microbiology & Virology>> Enterovirus>>WIN 54954

WIN 54954

رقم الكتالوجGC63291

WIN 54954 هو عامل مضاد للفيروسات النشط شفويا واسع الطيف

Products are for research use only. Not for human use. We do not sell to patients.

WIN 54954 التركيب الكيميائي

Cas No.: 107355-45-3

الحجم السعر المخزون الكميّة
10mM (in 1mL DMSO)
149٫00
متوفر
5 mg
135٫00
متوفر
10 mg
225٫00
متوفر
25 mg
405٫00
متوفر
50 mg
675٫00
متوفر
100 mg
1215٫00
متوفر

Tel:(909) 407-4943 Email: sales@glpbio.com

مراجعات العميل

بناء على آراء العملاء.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents

WIN 54954 is an orally active and broad-spectrum antipicornavirus agent. WIN 54954 is effectiveness against human rhinovirus, echovirus 9 and enterovirus infections[1][2].

WIN 54954 reduces plaque formation of 50 of 52 rhinovirus serotypes (MICs ranges from 0.007 to 2.2 μg/mL)[1].WIN 54954 inhibits 15 commonly isolated enteroviruses, with an EC80 of 0.06 μg/mL[1].

WIN 54954 (2-100 mg/kg; p.o.) protects 50% of the mice from developing paralysis following infection with coxsackievirus A-9 and echovirus-9 at the dose of 2 and 100 mg/kg, respectively[1].

[1]. Woods MG, et, al. In vitro and in vivo activities of WIN 54954, a new broad-spectrum antipicornavirus drug. Antimicrob Agents Chemother. 1989 Dec;33(12):2069-74.
[2]. Fechner H, et, al. Pharmacological and biological antiviral therapeutics for cardiac coxsackievirus infections. Molecules. 2011 Oct 11;16(10):8475-503.

مراجعات

Review for WIN 54954

Average Rating: 5 ★★★★★ (Based on Reviews and 19 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for WIN 54954

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.